Meeting
2016 Gastrointestinal Cancers Symposium
Novel drug discovery by pharmacogenomic profiling of 36 colorectal cancer cell lines.
Authors
Peter Eide
Molecular Genetics Group, Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radiumhospital, Oslo, Norway
Peter Eide , Jarle Bruun , Anita Sveen , Astrid Murumägi , John Mpindi , Mariliina Arjama , Olli Kallioniemi , Ragnhild A Lothe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 604)
DOI
10.1200/jco.2016.34.4_suppl.604
Abstract #
604
Poster Bd #
F9
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Screening of 129 FDA approved anti-cancer drugs in colorectal cancer cell lines resistant to oxaliplatin or irinotecan (SN38).
First Author: Jan Stenvang
Poster
2014 Gastrointestinal Cancers Symposium
The safety of chemotherapy for colorectal cancer patients with hepatitis C virus infection.
First Author: Kenji Tomizawa
Poster
2024 ASCO Annual Meeting
Phase 2 randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer.
First Author: Kanwal Pratap Singh Raghav
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with mXELIRI as second-line treatment in advanced colorectal cancer pretreated with bevacizumab plus standard chemotherapy: A single-arm, phase IB/II study.
First Author: Xin Qu